Targeting sphingosine kinase-1 to inhibit melanoma

Pigment Cell and Melanoma Research

Volumn 25, Issue 2, 2012, Pages 259-274

  Madhunapantula, Subbarao V ^a,b,c   Hengst, Jeremy ^a   Gowda, Raghavendra ^a   Fox, Todd E ^a   Yun, Jong K ^a   Robertson, Gavin P ^a,b,c,d  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Foreman Foundation for Melanoma Research   (United States)

^c PENN STATE CANCER INSTITUTE   (United States)

^d Department of Pathology ^*  (United States)

Author keywords

V600EB RAF; AKT3; Apoptosis; Melanoma; PRAS40; Proliferation; S 1 P; SKI I; Sphingosine kinase 1; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CERAMIDE; CYCLIN D1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 1 INHIBITOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DOWN-REGULATION; FIBROBLASTS; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LYSOPHOSPHOLIPIDS; MELANOCYTES; MELANOMA; MICE; MOLECULAR TARGETED THERAPY; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SKIN NEOPLASMS; SPHINGOSINE; STAUROSPORINE; THIAZOLES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84857389943     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2012.00970.x     Document Type: Article

References (66)

1. Ader, I., Brizuela, L., Bouquerel, P., Malavaud, B., and Cuvillier, O. (2008). Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res. 68, 8635-8642.
2. Antoon, J.W., Meacham, W.D., Bratton, M.R., Slaughter, E.M., Rhodes, L.V., Ashe, H.B., Wiese, T.E., Burow, M.E., and Beckman, B.S. (2011). Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J. Mol. Endocrinol. 28, 205-216.
3. Aplin, A.E., Kaplan, F.M., and Shao, Y. (2011). Mechanism of resistance to RAF inhibitors in melanoma. J. Invest. Dermatol. 131, 1817-1820.
4. Bektas, M., Jolly, P.S., Muller, C., Eberle, J., Spiegel, S., and Geilen, C.C. (2005). Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24, 178-187.
5. Beljanski, V., Knaak, C., Zhuang, Y., and Smith, C.D. (2011). Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest. New Drugs 29, 1132-1142.
6. Cheung, M., Sharma, A., Madhunapantula, S.V., and Robertson, G.P. (2008). Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 68, 3429-3439.
7. Edsall, L.C., Cuvillier, O., Twitty, S., Spiegel, S., and Milstien, S. (2001). Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. J. Neurochem. 76, 1573-1584.
8. Ernst, D.S., Eisenhauer, E., Walnman, N., Davis, M., Lohmann, R., Baetz, T., Belanger, K., and Smylie, M. (2005). Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest. New Drugs 23, 569-575.
9. Flaherty, K.T., Puzanov, K., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
10. Francy, J.M., Nag, A., Conroy, E.J., Hengst, J.A., and Yun, J.K. (2007). Sphingosine kinase 1 expression is regulated by signaling through PI3K, AKT2, and mTOR in human coronary artery smooth muscle cells. Biochim. Biophys. Acta. 1769, 253-265.
11. French, K.J., Schrecengost, R.S., Lee, B.D., Zhuang, Y., Smith, S.N., Eberly, J.L., Yun, J.K., and Smith, C.D. (2003). Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63, 5962-5969.
12. French, K.J., Upson, J.J., Keller, S.N., Zhuang, Y., Yun, J.K., and Smith, C.D. (2006). Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther. 318, 596-603.
13. Guan, H., Song, L., Cai, J., Huang, Y., Wu, J., Yuan, J., Li, J., and Li, M. (2011). Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS One 6, e19946.
14. Guo, D., Ye, J., Dai, J., Li, L., Chen, F., Ma, D., and Ji, C. (2008). Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. Leuk. Res. 33, 678-685.
15. Hait, N.C., Oskeritzian, C.A., Paugh, S.W., Milstien, S., and Spiegel, S. (2006). Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta 1758, 2016-2026.
16. Han, W.S., Yoo, J.Y., Youn, S.W., Kim, D.S., Park, K.C., Kim, S.Y., and Kim, K.H. (2002). Effects of C2-ceramide on the Malme-3M melanoma cell line. J. Dermatol. Sci. 30, 10-19.
17. Hengst, J.A., Guilford, J.M., Conroy, E.J., Wang, X., and Yun, J.K. (2010a). Enhancement of sphingosine kinase 1 catalytic activity by deletion of 21 amino acids from the COOH-terminus. Arch. Biochem. Biophys. 494, 23-31.
18. Hengst, J.A., Wang, X., Sk, U.H., Sharma, A.K., Amin, S., and Yun, J.K. (2010b). Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg. Med. Chem. Lett. 20, 7498-7502.
19. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., and Tuveson, D.A. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 5198-5202.
20. Hocker, T.L., Singh, M.K., and Tsao, H. (2008). Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J. Invest. Dermatol. 128, 2575-2595.
21. Huwiler, A., and Zangemeister-Wittke, U. (2007). Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit. Rev. Oncol. Hematol. 63, 150-159.
22. Inamdar, G.S., Madhunapantula, S.V., and Robertson, G.P. (2010). Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem. Pharmacol. 80, 624-637.
23. Kapitonov, D., Allegood, J.C., Mitchell, C. et al. (2009). Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 69, 6915-6923.
24. Lavieu, G., Scarlatti, F., Sala, G., Carpentier, S., Levade, T., Ghidoni, R., Botti, J., and Codogno, P. (2006). Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J. Biol. Chem. 281, 8518-8527.
25. Leclercq, T.M., and Pitson, S.M. (2006). Cellular signalling by sphingosine kinase and sphingosine 1-phosphate. IUBMB Life 58, 467-472.
26. Lee, J.T., Li, L., Brafford, P.A. et al. (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res. 23, 820-827.
27. Leroux, M.E., Auzenne, E., Evans, R., Hail Jr, N., Spohn, W., Ghosh, S.C., Farquhar, D., McDonnell, T., and Klostergaard, J. (2007). Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate 67, 1699-1717.
28. Li, W., Yu, C.P., Xia, J.T. et al. (2009). Phingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res. 15, 1393-1399.
29. Madhunapantula, S.V., and Robertson, G.P. (2008). Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res. 68, 5-8.
30. Madhunapantula, S.V., and Robertson, G.P. (2009). The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22, 400-419.
31. Madhunapantula, S.V., Sharma, A., and Robertson, G.P. (2007). PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 67, 3626-3636.
32. Madhunapantula, S.V., Desai, D., Sharma, A., Huh, S.J., Amin, S., and Robertson, G.P. (2008). PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. Mol. Cancer Ther. 7, 1297-1308.
33. Melendez, A.J., Carlos-Dias, E., Gosink, M., Allen, J.M., and Takacs, L. (2000). Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene 251, 19-26.
34. Miller, A.V., Alvarez, S.E., Spiegel, S., and Lebman, D.A. (2008). Sphingosine kinases and sphingosine-1-phosphate are critical for transforming growth factor beta-induced extracellular signal-regulated kinase 1 and 2 activation and promotion of migration and invasion of esophageal cancer cells. Mol. Cell. Biol. 28, 4142-4151.
35. Nava, V.E., Hobson, J.P., Murthy, S., Milstien, S., and Spiegel, S. (2002). Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp. Cell Res. 281, 115-127.
36. Nemoto, S., Nakamura, M., Osawa, Y. et al. (2009). Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J. Biol. Chem. 284, 10422-10432.
37. Nogueira, C., Kim, K.H., Sung, H., Paraiso, K.H., Dannenberg, J.H., Bosenberg, M., Chin, L., and Kim, M. (2010). Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 29, 6222-6232.
38. Olivera, A., Kohama, T., Edsall, L., Nava, V., Cuvillier, O., Poulton, S., and Spiegel, S. (1999). Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol. 147, 545-558.
39. Pchejetski, D., Doumerc, N., Golzio, M., Naymark, M., Teissie, J., Kohama, T., Waxman, J., Malavaud, B., and Cuvillier, O. (2008). Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol. Cancer Ther. 7, 1836-1845.
40. Pitson, S.M. (2011). Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci. 36, 97-107.
41. Pitson, S.M., Xia, P., Leclercq, T.M., Moretti, P.A., Zebol, J.R., Lynn, H.E., Wattenberg, B.W., and Vadas, M.A. (2005). Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J. Exp. Med. 201, 49-54.
42. Ren, S., Xin, C., Pfeilschifter, J., and Huwiler, A. (2010). A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation. Cell Physiol. Biochem. 26, 97-104.
43. Robertson, G.P. (2005). Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 24, 273-285.
44. Sarkar, S., Maceyka, M., Hait, N.C., Paugh, S.W., Sankala, H., Milstien, S., and Spiegel, S. (2005). Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 579, 5313-5317.
45. Schadendorf, D., Flchtner, I., Makki, A., Alljagic, S., Kupper, M., Mrowletz, U., and Henz, B.M. (1996). Metastatic potential of human melanoma cells in nude mice-characterization of phenotype, cytokine-secretion and tumor-associated antigens. Br. J. Cancer 74, 194-199.
46. Schnitzer, S.E., Weigert, A., Zhou, J., and Brune, B. (2009). Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol. Cancer Res. 7, 393-401.
47. Sharma, A., Trivedi, N.R., Zimmerman, M.A., Tuveson, D.A., Smith, C.D., and Robertson, G.P. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 2412-2421.
48. Sharma, A., Tran, M.A., Liang, S., Sharma, A.K., Amin, S., Smith, C.D., Dong, C., and Robertson, G.P. (2006). Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res. 66, 8200-8209.
49. Sharma, A.K., Sharma, A., Desai, D., Madhunapantula, S.V., Huh, S.J., Robertson, G.P., and Amin, S. (2008). Synthesis and anticancer activity comparison of phenylalkyl isoselenocyanates with corresponding naturally occurring and synthetic isothiocyanates. J. Med. Chem. 51, 7820-7826.
50. Shida, D., Takabe, K., Kapitonov, D., Milstien, S., and Spiegel, S. (2008). Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets 9, 662-673.
51. Shin, J.H., Choi, G.S., Kang, W.H., and Myung, K.B. (2007). Sphingosine 1-phosphate triggers apoptotic signal for B16 melanoma cells via ERK and caspase activation. J. Korean Med. Sci. 22, 298-304.
52. Shin, S.S., Wall, B.A., Goydos, J.S., and Chen, S. (2010). Akt2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res. 23, 103-111.
53. Singh, M., Lin, J., Hocker, T.L., and Tsao, H. (2008). Genetics of melanoma tumorigenesis. Br. J. Dermatol. 158, 15-21.
54. Sinnberg, T., Lasithiotakis, K., Niessner, H. et al. (2009). Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J. Invest. Dermatol. 129, 1500-1515.
55. Smalley, K.S., and Herlyn, M. (2006). Towards the targeted therapy of melanoma. Mini Rev. Med. Chem. 6, 387-393.
56. Smalley, K.S., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., and Herlyn, M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 1136-1144.
57. Solit, D.B., and Rosen, N. (2011). Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364, 772-774.
58. Song, L., Xiong, H., Li, M., Liao, W.T., Wang, L., and Wu, J. (2011). Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-{kappa}B pathway in human non-small cell lung cancer. Clin. Cancer Res. 17, 1839-1849.
59. Spiegel, S., and Milstien, S. (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. 4, 397-407.
60. Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010.
61. Tran, M.A., Gowda, R., Sharma, A., Park, E.J., Adair, J., Kester, M., Smith, N.B., and Robertson, G.P. (2008a). Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res. 68, 7638-7649.
62. Tran, M.A., Smith, C.D., Kester, M., and Robertson, G.P. (2008b). Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res. 14, 3571-3581.
63. Tuveson, D.A., Weber, B.L., and Herlyn, M. (2003). BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4, 95-98.
64. Vadas, M., Xia, P., McCaughan, G., and Gamble, J. (2008). The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim. Biophys. Acta 1781, 442-447.
65. Wijesinghe, D.S., Allegood, J.C., Gentile, L.B., Fox, T.E., Kester, M., and Chalfant, C.E. (2010). Use of high performance liquid chromatography-electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levels. J. Lipid Res. 51, 641-651.
66. Xia, P., Gamble, J.R., Wang, L., Pitson, S.M., Moretti, P.A., Wattenberg, B.W., D'Andrea, R.J., and Vadas, M.A. (2000). An oncogenic role of sphingosine kinase. Curr. Biol. 10, 1527-1530.